Answers are grounded in this paper and cite their sources.
The current data confirm the long-term efficacy of nilotinib 400 mg twice daily in patients with CP-CML. A majority of patients can achieve sustained MR4.5.
No takes yet. Share an insight, caveat, or question.
Masárová et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: